Overcoming Solid Tumor Challenges with ARTEMIS® Antibody Redirected T-Cell Therapy

Time: 2:45 pm
day: Bootcamp Day


  • Designing ARTEMIS® Antibody TCR (AbTCR) T-cells to address the major hurdles in treating solid tumor
  • Infiltrating into solid tumor under immunosuppressive microenvironment
  • Targeting Alpha-fetoprotein (AFP) and Glypican 3 (GPC3) in advanced hepatocellular carcinoma (HCC)
  • Demonstrating superior safety and efficacy profile of ARTEMIS® T-cells